We focus on immune targets – the key to unlocking new and effective cancer therapies. Our unique and innovative platform identifies novel immune targets we can modulate with new drugs.
We combine cutting-edge science, real-world clinical insights and unique autologous cell systems (i.e. cancer and immune cells from the same patient) to drive the development of immuno-oncology therapies. Our lead drug has completed IND-enabling studies and is planned to enter clinical Phase I in 2026.
We are committed to delivering pioneering solutions that directly influence patient care. Our discovery platform is patient-derived and able to discover new ways to fight cancer. Over 20% of the immune targets we have discovered*, have reached the stage of clinical trials by pharma companies.
*(IIA-supported research)
4C Biomed brings together a seasoned team of researchers and scientists with over a century of combined experience in biology, immunology and oncology, committed to the same goal – transforming cancer treatment.
This website uses cookies and similar technologies such as web beacons and pixels (collectively: “cookies”). These cookies are required in order to load our website or to enable you to use certain services that our website offers. We cannot provide you with access to the website or services without these cookies, and therefore these cookies cannot be disabled. For more details, you can read our privacy policy here.